Levamlodipine

Summary

Levamlodipine (CHEMBL2111097) is an approved small molecule (ATC C08CA17); indicated across 2 conditions including cardiovascular disorder and hypertensive disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: C08CA17
• Indications: 2 conditions
• Clinical trials: 16
• Chemistry: 408.9 Da · C20H25ClN2O5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2111097
Name	Levamlodipine
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	9822750
ChEBI	CHEBI:53796
ATC	C08CA17
Molecular formula	C20H25ClN2O5
Molecular weight	408.9
InChIKey	HTIQEAQVCYTUBX-KRWDZBQOSA-N

SMILES: CCOC(=O)C1=C(NC(=C([C@@H]1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN

IUPAC name: 3-O-ethyl 5-O-methyl (4S)-2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate

ChEBI definition: The (4S)-enantiomer of amlodipine.

Also known as: Amlodipine, (s)-, Levamlodipine, Levamlodipine component of agsav301, Levamlodipino, S-amlodipine, LEVAMLODIPINE, levamlodipine

Parent form; salt/anhydrous children: CHEMBL2107350, CHEMBL4594288

Patent coverage: 5,283 distinct patent families (15,958 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 15,956 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 11 (assay-derived). Sample: Alpha-2A adrenergic receptor, D(1A) dopamine receptor, Thromboxane A2 receptor, 5-hydroxytryptamine receptor 1A, Muscarinic acetylcholine receptor M1, Sodium-dependent noradrenaline transporter, Alpha-1A adrenergic receptor, Mu-type opioid receptor, D(3) dopamine receptor, Sodium-dependent dopamine transporter.

Bioactivity

ChEMBL activities: 4 potent at pChembl ≥ 5 of 11 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
SLC6A3	5.36	AC50	4348	nM	CHEMBL_ACT_25125044
ADRA2A	5.36	AC50	4331	nM	CHEMBL_ACT_25156514
DRD3	5.33	AC50	4623	nM	CHEMBL_ACT_25194607
TBXA2R	5.18	AC50	6586	nM	CHEMBL_ACT_25211179

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
cardiovascular disorder	4	MONDO:0004995	EFO:0000319
hypertensive disorder	3	MONDO:0005044	EFO:0000537

Clinical trials

Total trials: 16.

Phase distribution

Phase	Trials
PHASE3	6
PHASE1	6
PHASE4	1
PHASE2/PHASE3	1
PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01131546	PHASE4	COMPLETED	Efficacy and Safety of Levamlodipine Besylate Compared to Amlodipine Maleate in Patients With Essential Hypertension
NCT06771245	PHASE3	NOT_YET_RECRUITING	A Phase III Clinical Trial Evaluating the Efficacy and Safety of Valsartan/Levamlodipine (SYH9056) Tablets In Hypertensive Patients
NCT00289406	PHASE3	COMPLETED	Efficacy and Safety Study of S-Amlodipine Gentisate Compared to Amlodipine Besylate to Treat Mild-to-Moderate Hypertension
NCT01501253	PHASE3	COMPLETED	CKD-828 S-Amlodipine Non-Responder Trial
NCT01634295	PHASE3	COMPLETED	Efficacy and Safety of CKD-828 to Stage 2 Hypertension
NCT01983735	PHASE3	UNKNOWN	Efficacy and Safety of TELMINUVO to Stage 2 Hypertension
NCT03814109	PHASE3	WITHDRAWN	Efficacy and Safety of Leningrado Association in the Treatment of Hypertension
NCT04740840	PHASE2/PHASE3	COMPLETED	Anti Inflammatory Treatment of Hypertension
NCT01128322	PHASE2	COMPLETED	CKD-828 Primary Hypertension Trial(Dose-selection)
NCT01356043	PHASE1	COMPLETED	CKD-828 Drug Interaction Study (S-amlodipine)
NCT02047175	PHASE1	COMPLETED	CKD-346 DDI Study(Telmisartan/S-Amlodipine, Rosuvastatin)
NCT02250833	PHASE1	COMPLETED	CKD-828 (80/5mg) Pharmacokinetic Study
NCT02358824	PHASE1	COMPLETED	CKD-828 (80/5mg) Pharmacokinetic Study
NCT03657550	PHASE1	COMPLETED	Bioavailability of 5 mg of Levamlodipine Maleate Tablets Versus 10 mg of Amlodipine Besylate Tablet in Healthy Subjects
NCT04411875	PHASE1	COMPLETED	Bioequivalence of Levamlodipine Besylate Tablets in Healthy Chinese Subjects
NCT04554303	Not specified	UNKNOWN	Comparing Safety and Efficacy of Amlodipine Verses S Amlodipine in Patients With Essential Hypertension

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).